For the first time ever, Mount Sinai researchers have identified a protein as a marker that can indicate whether a cancer patient will develop a reoccurrence of lethal, metastatic cancer, according to a clinical study published in Breast Cancer Research in October.
The researchers found that when cells from a breast cancer patient’s original tumor metastasized into the patient’s bone marrow with none, or only a small amount, of the protein NR2F1, the patients all soon died. However, patients who had a high concentration of NR2F1 in the cancer cells in their bone marrow did not frequently develop this type of metastatic cancer, and lived longer. The presence of a high concentration of NR2F1 induced dormancy in the cancer cells, essentially deactivating them, so this research shows that survival in these patients is due to the dormancy of the disseminated cancer.
These findings suggest that the absence of this protein in cancer cells that have spread to a patient’s bone marrow can reliably signal that the patient will relapse soon and that additional treatment is needed, while if the protein is present, the cancer cells are dormant and the patient can be monitored rather than undergo unnecessary treatment. This research is particularly important because the most common breast type of breast cancer, when it metastasizes, almost always goes to the bone.
The research is especially important in the United States because bone marrow tests, called aspirates, are not used to monitor patients there. The study was a collaboration with physicians and scientists in Oslo, Norway, where bone marrow aspirates are used to monitor patients. The laboratory of Bjorn Naume from University Hospital of Oslo collaborated with the Aguirre-Ghiso and Sosa labs at the Icahn School of Medicine at Mount Sinai and conducted the analysis of the patients’ samples from their clinical trials, thus contributing significantly to this research.
Using this research, physicians could monitor their patients with bone marrow aspirates. Tests for the protein could also help clinicians identify patients who may benefit from recently identified drugs that were shown to target cancer cells and render or keep them dormant. Studies have already shown that androgen deprivation treatment, an anti-hormone therapy used in prostate cancer, has been linked to increasing levels of the NR2F1 protein. Mount Sinai, through a trial funded by the V Foundation for Cancer Research and The Tisch Cancer Institute at the Icahn School of Medicine, has already begun recruiting prostate cancer patients for a test of the ability of two drugs to induce dormancy through NR2F1 upregulation. “This research shows that the survival advantage in these patients is due to high levels of this protein. Tests using this protein marker could further improve curative treatment of breast cancer, sparing patients from unnecessary treatments. Identifying patients with disseminated disease that is not yet symptomatic and characterizing it for potential dormancy or metastatic recurrence is a game changer,” said lead researcher Julio Aguirre-Ghiso, PhD, Director of Solid Tumor and Metastasis Research, Director of Head and Neck Cancer Basic Research, and Professor of Oncological Sciences, Otolaryngology, and Medicine (Hematology and Medical Oncology) at The Tisch Cancer Institute at the Icahn School of Medicine. “Improved techniques to assess the population of patients with residual disease and their dormant or reactivating state will be key to identifying the risk of future metastasis despite undergoing standard treatment. This opens the way for testing new treatments that prevent metastasis by inducing dormancy or eradicating the dormant disseminated cancer cells that have not yet initiated metastatic growth.”
The Latest on: Breast cancer
via Google News
The Latest on: Breast cancer
- Breast Cancer Market Expected to Grow at Approx CAGR of 9.2% Till 2023 | By Types Invasive Ductal Carcinoma, Invasive Lobular Carcinoma and Other on February 25, 2019 at 4:20 am
According to a recent study published by the Market Research Future analysts, the global breast cancer market is growing at a moderate growth rate; mainly due to rise in the prevalence rate of the bre... […]
- Breast cancer survivor shares brave photo of her double mastectomy scars before boob op – and says ‘all women need to see this’ on February 25, 2019 at 3:36 am
A woman has shared pictures of how her body has changed following her diagnosis The 44-year-old woman posted pictures of how her body had changed since she discovered a lump after accidentally knockin... […]
- This startup uses artificial intelligence to detect breast cancer early; raises $6 million on February 25, 2019 at 12:59 am
Bengaluru-based health-tech startup Niramai that uses artificial intelligence to detect breast cancer at the early stage has raised $6 million in funding. The round was led by Japan-based venture capi... […]
- Researchers harness machine learning to predict breast cancer on February 25, 2019 at 12:10 am
A Dartmouth research team is harnessing machine learning technology to predict malignant breast cancer lesions. Saeed Hassanpour, assistant professor of biomedical data science and epidemology at the ... […]
- Diamond Morrison Helps Mother Through Battle With Breast Cancer on February 24, 2019 at 9:36 pm
LAFAYETTE, LA. (KLFY) Saturday, the Ragin Cajuns Women's Basketball team hosted their annual pink game. It was a day dedicated to fighting cancer, a disease that hits home for several of the cajuns. F... […]
- Researchers create possible blood test to detect breast cancer on February 24, 2019 at 12:53 pm
A team of German doctors may have discovered a major potential breakthrough in detecting breast cancer. The doctors possibly may have found a blood test that can help with early detection. They're cal... […]
- Nutrition can beat breast cancer on February 23, 2019 at 4:00 pm
Good nutrition helps one’s body to heal better. And this dictum holds true even for life-threatening diseases such as cancer. It is estimated that about 9 percent of breast cancer patients could have ... […]
- Fundraiser to help Pct. 4 deputy fighting breast cancer on February 23, 2019 at 5:50 am
Brittney Buchkar, patrol deputy with Harris County Constable Pct. 4, and her daughter Allison smile while taking a selfie. Brittney Buchkar, patrol deputy with Harris County Constable Pct. 4, and her ... […]
- Global $21 Billion Breast Cancer Screening Market to 2024 - Increasing Women's Breast Cancer Care, Treatment & Awareness Initiatives on February 22, 2019 at 6:15 am
DUBLIN, Feb. 22, 2019 /PRNewswire/ -- The "Breast Cancer Screening Market, Population, By Screening Tests, By Countries" report has been added to ResearchAndMarkets.com's offering. Breast Cancer Scree... […]
via Bing News